Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel ...

Quest expects the new blood test will support response monitoring in clinical trials.

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...

Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

GNC, the worldwide leader in health and wellness, today announced the launch of the newly reformulated GNC AMP Wheybolic, the ...

Researchers have found in a new research that beyond preventing herpes zoster, the shingles vaccine may be associated with ...

Explore how biochemistry, microbiology, and pathology collaborate in cancer care for early detection, personalized treatment, and survival monitoring.

By Vijay Kumar Malesu Why mismatched resistance thresholds between CLSI and EUCAST could be masking the true scale of ...

This expansion marks a significant milestone in the company's continued national growth, extending EmeritusDX's operational footprint beyond California and Pennsylvania and positioning the ...

Researchers reprogrammed bacterial bridge recombinases to edit large genomic regions in mammalian cells, revealing a ...